EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Updates for Cardio‐Kidney Protective Effects by Angiotensin Receptor‐Neprilysin Inhibitor: Requirement for Additional Evidence of Kidney Protection

Shunichiro Tsukamoto iD, Tatsuki Uehara, Kengo Azushima, Hiromichi Wakui, Kouichi Tamura

Journal of the American Heart Association · 18.04.2023 · 12 (8)

DOI: 10.1161/jaha.122.029565 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of the American Heart Association, erschienen am 18.04.2023. Verfasst von Shunichiro Tsukamoto und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Science and Cardiorenal Medicine Yokohama City University Graduate School of Medicine Yokohama Japan. Hauptthemen laut MEDLINE: Heart Failure, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The incidence of heart failure and chronic kidney disease is increasing, and many patients develop both diseases. Angiotensin receptor‐neprilysin inhibitor (ARNI) is a promising therapeutic candidate for both diseases. ARNI has demonstrated superior cardioprotective effects compared with renin–angiotensin system inhibitors (RAS‐Is) in large clinical trials such as the PARADIGM‐HF (Prospective Comparison of ARNI With ACEI [Angiotensin‐Converting Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial. It has also been suggested that ARNI can provide renoprotective effects beyond those of RAS‐Is in patients with HF. ARNI might have beneficial effects on the kidneys because of its ability to improve cardiac function in patients with heart failure and affect renal hemodynamics by enhancing the effects of hormones such as natriuretic peptide. In contrast, in the PARADIGM‐HF trial, ARNI was associated with more albuminuria compared with RAS‐I; thus, it is unclear whether long‐term ARNI therapy has renoprotective effects. Additionally, ARNI did not provide renoprotective effects beyond RAS‐I in patients with chronic kidney disease in the UK HARP‐III (United Kingdom Heart and Renal Protection‐III) trial. In other words, the patient population in which ARNI is more renoprotective than RAS‐I might be limited. Collectively, ARNI may have renoprotective effects in addition to cardioprotective effects, but the evidence to date is applicable only to heart failure. Theoretically, given the molecular mechanism of ARNI, it could also be renoprotective in conditions such as nephrosclerosis, which has low risks of albuminuria and reduced kidney perfusion, but the evidence for such effects is lacking. Further research is needed to clarify whether ARNI therapy is an acceptable treatment strategy for renal protection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureRenal Insufficiency, ChronicHumansValsartanNeprilysinTetrazolesReceptors, AngiotensinAlbuminuriaAngiotensin Receptor AntagonistsDrug CombinationsAntihypertensive AgentsKidneyEnzyme InhibitorsBiphenyl CompoundsStroke Volume

Stichwörter der Autor:innen

albuminuriaangiotensin receptor‐neprilysin inhibitorchronic kidney diseaseheart failurekidney‐protective effectrenin–angiotensin system inhibitors

Substanzen

ValsartanNeprilysinTetrazolesReceptors, AngiotensinAngiotensin Receptor AntagonistsDrug CombinationsAntihypertensive AgentsEnzyme InhibitorsBiphenyl Compounds

Autor:innen und Institutionen

  • Department of Medical Science and Cardiorenal Medicine Yokohama City University Graduate School of Medicine Yokohama Japan.

ORCID-Profile: Shunichiro Tsukamoto

Zitieren

APA

Tsukamoto, S., Uehara, T., Azushima, K., Wakui, H., & Tamura, K. (2023). Updates for Cardio‐Kidney Protective Effects by Angiotensin Receptor‐Neprilysin Inhibitor: Requirement for Additional Evidence of Kidney Protection. Journal of the American Heart Association, 12(8). https://doi.org/10.1161/jaha.122.029565

Vancouver

Tsukamoto S, Uehara T, Azushima K, Wakui H, Tamura K. Updates for Cardio‐Kidney Protective Effects by Angiotensin Receptor‐Neprilysin Inhibitor: Requirement for Additional Evidence of Kidney Protection. Journal of the American Heart Association. 2023;12(8). doi:10.1161/jaha.122.029565

BibTeX
@article{Tsukamoto2023,
  author = {Tsukamoto, Shunichiro and Uehara, Tatsuki and Azushima, Kengo and Wakui, Hiromichi and Tamura, Kouichi},
  title = {Updates for Cardio‐Kidney Protective Effects by Angiotensin Receptor‐Neprilysin Inhibitor: Requirement for Additional Evidence of Kidney Protection},
  journal = {Journal of the American Heart Association},
  year = {2023},
  volume = {12},
  number = {8},
  doi = {10.1161/jaha.122.029565}
}
Kostenlos starten →